Effects of zinc and thyroxine treatment on dietary-obese mice

Altered thyroid hormone metabolism is known to be an important factor contributing to the defective expression of thermogenesis in the obese mouse, and the action of zinc on thyroid hormone conversion may be an important factor in the energy metabolism of obesity. The effects of zinc and thyroxine treatment on dietary-obese mice were examined. The dietary-obese mice were successfully induced by high-fat diet (80% fat), and every mouse was administered daily 1.25 mg zinc sulfate and/or 5 micrograms thyroxine. After 8 weeks of treatment, serum zinc, serum triacylglycerols and body fat composition were determined. On high-fat diets, fat deposition was found in male mice treated with zinc sulfate. However, when mice were treated with zinc and thyroxine at the same time, serum triacylglycerols and body fat composition decreased significantly on both basal and high-fat diets. When mice were treated with thyroxine alone, body fat composition decreased significantly, but there was no significant effect on serum triacylglycerols on either diet. Obesity was significantly correlated with dietary fat, zinc and thyroid hormone. It is suggested that zinc may play an important role, through its action on thyroid hormone conversion and via insulin action, in the energy metabolism of dietary-obese mice.

Long term treatment of Graves' disease with iopanoic acid (Telepaque)

To investigate the long term utility of the cholecystographic contrast agent iopanoic acid (Telepaque) for treatment of Graves' hyperthyroidism, we studied 40 patients treated with 500 mg, orally, daily for 1-12 months. We measured thyroid size; body weight; serum T3, T4, and free T4 concentrations; and antithyroglobulin and antimicrosomal antibody levels at monthly intervals. Based on the effects of the therapy, the patients were divided into 3 groups: 6 patients had excellent responses with return of serum thyroid hormone levels to normal (group A); 12 patients had fair responses, but 1 thyroid hormone test remained elevated (group B); and 22 patients had minimal benefit (group C) with only slight clinical improvement and transient reduction of serum T3 concentration. Mean serum T3 levels decreased significantly after 1 month of therapy in all 3 groups and became normal in groups A and B, but the reduction in group C was not sustained. Mean serum T4 and free T4 levels remained above normal during the course of therapy in groups B and C. Sixty-eight percent of patients in group C had large goiters compared with 33% of group A and 25% of group B, and those in group C tended to have more severe biochemical hyperthyroidism initially. There were no significant changes in antibody titers during therapy. These data indicate that iopanoic acid is not effective therapy for many hyperthyroid patients.

Conformations of cyclic octapeptides. 4. Diastereomers of cyclo(Gly-Pro-Phe-Ala-Asn-Ala-Val-Ser)

Stereoisomers of cyclo(Gly-Pro-Phe-Ala-Asn-Ala-Val-Ser) were synthesized. NMR studies of their solution conformations, focusing on peptide N-H solvent exposure, were made. These indicated that a single proline residue in the cyclic octapeptide ring is insufficient constraint to stabilize the backbone conformations that were previously established for cyclo(Gly-Pro-Phe-Ala)2.

Amiodarone inhibits T4 to T3 conversion and alpha-glycerophosphate dehydrogenase and malic enzyme levels in rat liver

Amiodarone has been found to decrease serum T3 by blocking peripheral T4 5'-deiodinase. This reduction in T3 levels may contribute to the effectiveness of this drug in moderating cardiac arrhythmias. To further characterize the effect of amiodarone on thyroid hormone metabolism and biological action, male Sprague-Dawley rats were thyroidectomized and then fed 500 ug T4 or 50 ug T3 and 500 mg amiodarone/kg of powdered diet for 6 to 8 weeks. Hepatic and cardiac levels of T4, T3, alpha-glycerophosphate dehydrogenase (GPD) and malic enzyme (ME) were used as indicators of thyroid hormone availability and action at the cellular level. Conversion of T4 to T3 was measured in liver homogenates. Serum TSH, T4 and T3 were also measured. Amiodarone reduced hepatic GPD and ME in thyroidectomized rats receiving dietary T4. Liver T4 levels were significantly increased by amiodarone and the T3/T4 ratio was reduced (P less than .05). Amiodarone inhibited hepatic T4 to T3 conversion and decreased serum T3. The decreased T3 action at the cellular level, indicated by the reduction in hepatic GPD and ME, is not due to pharmacologic effects of amiodarone since these enzyme levels were not affected by amiodarone in thyroidectomized rats replaced with T3.

Comparison of a new ultrafiltration method for serum free T4 and free T3 with two RIA kits in eight groups of patients

We measured serum free thyroxine (FT4) and free T3 (FT3) concentrations by a newly developed ultrafiltration (UF) method and by the Diagnostic Products Corporation (DPC) and Amersham Corporation (Amerlex) RIA methods in 173 patients divided into eight groups: 1) normal controls, II) normal elderly subjects, III) hyperthyroidism, IV) hypothyroidism, V) pregnancy, VI) critically ill, VII) chronic renal failure, and VIII) heparin therapy. The results were also compared with the free T4 index and free T3 index. FT4 (UF) and FT3 (UF) were generally normal in the elderly subjects. All methods showed elevated values in hyperthyroid patients. FT4 was normal in 7-23% of hypothyroid patients (depending on the method), and FT3 was normal in 15-27% of hypothyroid patients. Mean FT4 (UF) and FT3 (UF) were increased in pregnancy; in contrast the Amerlex RIA results were reduced in pregnancy. In critically ill patients, mean FT4 and FT3 were reduced by all methods. In heparinized patients, FT4 (UF) and FT3 (UF) were normal, but the RIA kits, especially Amerlex, gave very low values. Although the various methods gave considerably different absolute values of FT4 and FT3, there was a high degree of correlation between the ultrafiltration FT4 and FT3 and the results by the other methods.

Left ventricular mass and volume/mass ratio determined by two-dimensional echocardiography in normal adults

This study prospectively defined the range of left ventricular mass and volume/mass ratio determined by two-dimensional echocardiography in 84 normal adults. A modified Simpson's rule algorithm was used to calculate ventricular volumes from orthogonal two and four chamber apical views. An algorithm based on a model of the left ventricle as a truncated ellipsoid was used to calculate ventricular mass. Like left ventricular volumes, left ventricular mass values were larger in normal men than in women (mean 148 versus 108 g, p less than 0.001) and remained larger after correction for body surface area. Volume/mass ratios, however, were constant at end-diastole (0.80) and end-systole (0.26). The influence of age and heart rate on all variables in this normal group was minimal, and no correction for these variables was necessary. The definition of normal mass, volume and volume/mass ratios by two-dimensional echocardiography will facilitate the noninvasive, quantitative diagnosis of left ventricular hypertrophy and help clarify the relation between hypertrophy and systolic wall stress.

Studies on the reactivity of the essential sulfhydryl groups as a conformational probe for the fatty acid synthetase of chicken liver. Inactivation by 5,5'-dithiobis-(2-nitrobenzoic acid) and intersubunit cross-linking of the inactivated enzyme

Fatty acid synthetase of chicken liver is rapidly and reversibly inactivated by 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) at a rate (k2 = 132 mM-1 S-1 in 3 mM EDTA, 1% (v/v) glycerol, pH 7.0, at 25 degrees C) up to 2200 times higher than the reaction of this reagent with simple thiol compounds. The inactivation is caused by the reaction of the phosphopantetheine SH group, since it is protected competitively by either acetyl- or malonyl-CoA, and since the inactivated enzyme is unreactive with the phosphopantetheine label chloroacetyl-CoA but reactive with the cysteine reagent 1,3-dibromopropanone. Moreover, chloroacetyl-CoA prevents the modification of the rapidly reacting essential SH group by DTNB. The number of SH groups involved in inactivation was determined by correlating activity loss with the extent of reaction and by stopped-flow analysis of substrate (or chloroacetyl-CoA) protection. Values between 0.91 and 1.15 SH groups/dimer were obtained, indicating the presence of substoichiometric amounts of the prosthetic group in the fatty acid synthetase preparations used in this study. Inactivation of the synthetase by DTNB is strongly inhibited by increasing salt concentration and protected noncompetitively by NADP+ and NADPH. Treatment of the enzyme inactivated at low salt by salt, NADP+, or NADPH also effectively reduced cross-linking between enzyme subunits. The parallel effects of these treatments on the reaction with DTNB and subsequent dimerization are consistent with a minimum model of two discreet conformation states for fatty acid synthetase. In the low salt conformer, the phosphopantetheine and cysteine SH groups are juxtaposed, and the DTNB reaction (k2 approximately 132 mM-1 S-1) and dimerization are both facilitated. Transition to the high salt conformer by the above treatments is accompanied by an approximately 20-fold reduction of reactivity with DTNB (k2 = 6.8 mM-1 S-1) and reduced dimerization, due to spatial separation of the SH groups. During palmitate synthesis, the enzyme may oscillate between these conformation states to permit the reaction of intermediates at different active sites. Results obtained by studies on the effect of pH on DTNB inactivation implicate a pK of 5.9-6.1 for the essential SH group independent of salt concentration. This value is 1.5-1.8 pH units lower than the pK of 7.6-7.7 for CoA and may explain the 23-fold increase of the rate constant from a value of 0.3 mM-1 S-1 for CoA to that of the high salt conformer.

Improved ultrafiltration method for simultaneous measurement of free thyroxin and free triiodothyronine in serum

We describe a new ultrafiltration method for measuring concentrations of free thyroxin (FT4) and free triiodothyronine (FT3). Serum containing [131I]T4 and [125I]T3 is diluted 10-fold in phosphate buffer (500 mmol/L, pH 7.4 at 37 degrees C), then passed through a YMT membrane in an Amicon MPS-1 centrifugal ultrafiltration device. Radioactive iodide and protein-bound thyronines are separated from FT4 and FT3 in the ultrafiltrate by use of a Sephadex G-25 microcolumn. In normal controls, the fraction of T4 that passes into the ultrafiltrate is 0.021 +/- 0.006% (mean +/- SD), FT4 is 19.6 +/- 6.5 ng/L, the fraction of T3 that passes into the ultrafiltrate is 0.18 +/- 0.5%, and the FT3 is 2.03 +/- 0.50 ng/L. Intra-assay precision (CV) is 5.4% for FT4 and 4.2% for FT3; the respective interassay CVs are 10.1% and 8.0%. In various groups of patients with thyroid disease and other conditions that influence serum T4 and T3 concentrations, FT4 by ultrafiltration correlated with FT4 measured by equilibrium dialysis (r = 0.84, p less than 0.001) and FT3 by ultrafiltration correlated with FT3 measured by the Diagnostic Products RIA kit (r = 0.87, p less than 0.001). The accuracy, reproducibility, speed, and simplicity of the ultrafiltration method compared favorably with the more cumbersome method of equilibrium dialysis.

Improved ultrafiltration method for simultaneous measurement of free thyroxin and free triiodothyronine in serum

We describe a new ultrafiltration method for measuring concentrations of free thyroxin (FT4) and free triiodothyronine (FT3). Serum containing [131I]T4 and [125I]T3 is diluted 10-fold in phosphate buffer (500 mmol/L, pH 7.4 at 37 degrees C), then passed through a YMT membrane in an Amicon MPS-1 centrifugal ultrafiltration device. Radioactive iodide and protein-bound thyronines are separated from FT4 and FT3 in the ultrafiltrate by use of a Sephadex G-25 microcolumn. In normal controls, the fraction of T4 that passes into the ultrafiltrate is 0.021 +/- 0.006% (mean +/- SD), FT4 is 19.6 +/- 6.5 ng/L, the fraction of T3 that passes into the ultrafiltrate is 0.18 +/- 0.5%, and the FT3 is 2.03 +/- 0.50 ng/L. Intra-assay precision (CV) is 5.4% for FT4 and 4.2% for FT3; the respective interassay CVs are 10.1% and 8.0%. In various groups of patients with thyroid disease and other conditions that influence serum T4 and T3 concentrations, FT4 by ultrafiltration correlated with FT4 measured by equilibrium dialysis (r = 0.84, p less than 0.001) and FT3 by ultrafiltration correlated with FT3 measured by the Diagnostic Products RIA kit (r = 0.87, p less than 0.001). The accuracy, reproducibility, speed, and simplicity of the ultrafiltration method compared favorably with the more cumbersome method of equilibrium dialysis.